Head to Head Review: Kymera Therapeutics (NASDAQ:KYMR) and Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ:ACORGet Free Report) and Kymera Therapeutics (NASDAQ:KYMRGet Free Report) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, earnings, profitability, institutional ownership and analyst recommendations.

Analyst Ratings

This is a summary of current ratings for Acorda Therapeutics and Kymera Therapeutics, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Acorda Therapeutics 0 0 0 0 N/A
Kymera Therapeutics 0 6 6 0 2.50

Kymera Therapeutics has a consensus target price of $39.89, suggesting a potential downside of 1.70%. Given Kymera Therapeutics’ higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than Acorda Therapeutics.

Earnings and Valuation

This table compares Acorda Therapeutics and Kymera Therapeutics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Acorda Therapeutics $118.57 million 0.13 -$65.92 million ($17.11) -0.72
Kymera Therapeutics $78.59 million 31.55 -$146.96 million ($2.52) -16.10

Acorda Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Acorda Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Acorda Therapeutics and Kymera Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Acorda Therapeutics -14.35% -21.45% -4.25%
Kymera Therapeutics -187.00% -34.83% -25.30%

Volatility and Risk

Acorda Therapeutics has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.3, meaning that its share price is 130% more volatile than the S&P 500.

Summary

Acorda Therapeutics beats Kymera Therapeutics on 6 of the 11 factors compared between the two stocks.

About Acorda Therapeutics

(Get Free Report)

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. The company's product pipeline includes Cimaglermin alfa (GGF2), a member of neuregulin growth factor family which is in Phase 1 clinical trials for recovery of neurological injury, as well as to enhance heart function in animal models of heart failure. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York.

About Kymera Therapeutics

(Get Free Report)

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.